Company Overview and News

Eldorado Gold Stock Skyrocketed on May 22

2018-05-23 marketrealist
Eldorado Gold (EGO) stock suffered a great deal in 2017 due to the standoff with the Greek government and some technical issues at its Turkey mines. The company’s stock price fell ~56% in 2017 in addition to the YTD (year-to-date) decline of 33.6%. The VanEck Vectors Gold Miners ETF (GDX) and the SPDR Gold Shares (GLD) fell 3.9% and 0.9%, respectively, YTD. Agnico Eagle Mines (AEM), Yamana Gold (AUY), and IAMGOLD (IAG) returned -7.

Mining companies still reluctant to tap Argentina deposits

2018-05-23 reuters
BUENOS AIRES (Reuters) - Despite Argentine President Mauricio Macri’s pro-business policies, international mining companies are still reluctant to invest in Argentina amid a lack of regulatory clarity.

Miners Are Trading below 100-Day Averages: Could They Rebound?

2018-05-22 marketrealist
It seems precious metals’ rout has also affected precious metal mining companies’ stock prices. In this article, we’ll discuss moving averages, returns, and RSI (relative strength index) scores for Sibanye Gold (SBGL), Franco-Nevada (FNV), Yamana Gold (AUY), and Barrick Gold (ABX), which have fallen 43.1%, 11.1%, 8%, and 8.8%, respectively.

Top 20 Gold Stocks to Buy Despite Irrational Markets

2018-05-21 investorplace
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.

Yamana Gold (AUY) Produces First Gold & Silver at Cerro Moro

2018-05-21 zacks
Yamana Gold Inc. (AUY - Free Report) declared the first gold and silver production at its Cerro Moro mine located in Santa Cruz province, Argentina. The mine is a high-grade gold and silver operation sourcing ore from a combination of open pit and underground mining. Production ramp up at the mine remains on track and the company expects commercial production in second-quarter 2018. The mine is expected to produce 85,000 ounces of gold this year.

How Fall in Gold Prices Is Affecting Miners

2018-05-21 marketrealist
It seems that the rout in precious metals has also plagued the performance of precious metal mining companies. In this article, we’ll discuss Sibanye Gold (SBGL), Gold Fields (GFI), Yamana Gold (AUY), and Pan American Silver (PAAS), which have fallen 40.9%, 15.8%, and 10.3%, respectively. PAAS has risen 12.8% on a YTD basis.

Which Gold Miners Are Ray Dalio and John Paulson Betting On?

2018-05-18 marketrealist
Hedge funds increased their net positions in the SPDR Gold Shares ETF (GLD) during the first quarter. However, all isn’t so rosy for the VanEck Vectors Gold Miners ETF (GDX). During the quarter, GDX’s holdings fell 15.4% sequentially.

A Look at the Technicals of Miners in May

2018-05-16 marketrealist
After reviving compared to their previous losses, the four precious metals are in negative territory again. The revival of the US dollar had a negative impact on precious metals and mining stocks during the past few weeks. The settling of the market’s unrest could have also caused a withdrawal of haven bids.

Could Investors Keep Pouring Money into Gold ETFs?

2018-05-16 marketrealist
Gold ETF investors bought 173.4 tons of gold in 2017, which was 9% higher year-over-year. In 2018 year-to-date, the inflows in gold-backed ETFs have been strong. In times of increased volatility, investors are repositioning their portfolios to include more gold as a volatility hedge. Expectations of a global trade war triggered by President Trump’s import tariffs could lead investors to seek a haven in gold.

AUY / Yamana Gold Inc. FORM 6-K (Current Report of Foreign Issuer)


CANADA STOCKS - TSX rises 0.08 pct, extends winning streak

2018-05-15 reuters
NEW YORK, May 15 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 12.20 points, or 0.08 percent, to 16,097.81. * The biggest contributor to the TSX gain was Canadian National Railway Co, with 10.1 net index points. Industrials were the top sector contributor with 13 net points. * Leading the index were Element Fleet Management Corp, up 12.1 percent, Aphria Inc, up 7.5 percent, and Boyd Group Income Fund, higher by 4.

Negative Weekly Chart For Gold Futures Is An Opportunity To Buy These 4 Popular Gold Mining Stocks

2018-05-15 seekingalpha
Comex gold futures have a negative weekly chart and weakness is approaching my monthly value level for May at $1,292.7.

Focusing On Gold's Resilient Base

2018-05-11 seekingalpha
Gold trended higher in early April due to trade tensions between the U.S. and China, prospects of airstrikes on Syria, and heightened inflation expectations following a higher than expected March Producers Price Index (PPI)1 and a 2.1% annual rise in the core Consumer Price Index2. Gold topped at $1,365 per ounce on March 11. This level has been the proverbial price ceiling for gold since 2014.

A Look at the Correlation of Precious Metal Miners

2018-05-09 marketrealist
In this final part of the series, we’ll look at the correlation between gold and four mining stocks: Randgold Resources (GOLD), Yamana Gold (AUY), Coeur Mining (CDE), and Barrick Gold (ABX). Mining stocks generally move with gold prices. Among these four miners, Yamana Gold has shown the highest correlation with gold this year, while Randgold has the lowest correlation on a year-to-date basis.

Kinross Gold Reported a Solid Earnings Beat in 1Q18

2018-05-09 marketrealist
Kinross Gold (KGC) released its 1Q18 results after the market closed on May 8. The company reported EPS (earnings per share) of $0.10, which was double the consensus estimate of $0.05. Its revenue of $897 million also came in above the market’s expectation of $833 million.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 98462Y100